Anne Wojcicki’s TTAM Research Institute won a bankruptcy auction for 23andMe with a $305 million bid, surpassing Regeneron Pharmaceuticals. Despite objections regarding customer data transfer and ongoing litigation from a 2023 data breach, TTAM’s offer awaits judicial approval, while 23andMe shares have surged in anticipation of a recovery.
